Risk factors and Response of Branch Retinal Vein Occlusion induced Macular Edema to intravitreal injections of Triamcinolone and Bevacizumab

Purpose: To study the effects of combined intravitreal injections of bevacizumab (IVB) and triamcinolone acetonide (IVTA) in patients with non-resolving macular edema (ME) secondary to Branch Retinal Vein Occlusion (BRVO). Methods: In a prospective observational study, 50 pseudophakic eyes of BRVO patients with non-resolving central macular edema who had received more than 3 doses of IVB previously were injected with combination therapy of 1.25 mg/0.05 ml IVB and 4 mg of IVTA and followed up for 6 months with best corrected visual acuity(BCVA), intraocular pressure(IOP) and central macular thickness(CMT) Results: The mean BCVA was logMAR 0.75±0.25 at baseline and 0.65±0.15, 0.48±0.20, and 0.22±0.25 at 6weeks, 3 months and 6 months respectively. Mean CMT at baseline was 668.32±254.66 and 434.43±99.55, 243.22±58.92, and 220.83±42.60 at 6 weeks, 3 months and 6 months respectively. Baseline IOP measured was 16.5±3.1 mmHg which progressed to 19.6±3.4mmHg and 21.4±2.8mmHg at 6 weeks and 3 months respectively and decreased to 17.3±2.2 at 6 months. The most common adverse effect seen was increase in IOP in 24(48%)patients, out of which 3(6%) patients needed to start anti-glaucoma medication (AGM). 3(6%) patients had sub-conjunctival hemorrhage(SCH). Conclusion: The prolonged therapeutic effects of combination therapy leads to outstanding anatomical and visual outcome in non resolving ME due to BRVO, with fewer doses and thus fewer adverse effects.

Download Full-text

INTRAVITREAL INJECTIONS OF ZIV-AFLIBERCEPT FOR THE TREATMENT OF A PATIENT WITH MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION

Retinal Cases & Brief Reports ◽

10.1097/icb.0000000000000449 ◽

2018 ◽

Vol 12 (2) ◽

pp. 93-96 ◽

Cited By ~ 2

Author(s):

Gabriel Costa de Andrade ◽

João Rafael de Oliveira Dias ◽

André Maia ◽

Michel Eid Farah ◽

Somaia Mitne ◽

...

Keyword(s):

Macular Edema ◽

Retinal Vein Occlusion ◽

Branch Retinal Vein Occlusion ◽

Intravitreal Injections ◽

Vein Occlusion

Download Full-text

Initial Dose of Three Monthly Intravitreal Injections versus PRN Intravitreal Injections of Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion

BioMed Research International ◽

10.1155/2013/209735 ◽

2013 ◽

Vol 2013 ◽

pp. 1-8 ◽

Cited By ~ 6

Author(s):

Seong Joon Ahn ◽

Jeeyun Ahn ◽

Se Joon Woo ◽

Kyu Hyung Park

Keyword(s):

Macular Edema ◽

Retinal Vein Occlusion ◽

Initial Dose ◽

Branch Retinal Vein Occlusion ◽

Dose Group ◽

Intravitreal Bevacizumab ◽

Intravitreal Injections ◽

Vein Occlusion ◽

Corrected Visual Acuity ◽

Initial Injection

Purpose. To compare visual and anatomic outcomes of intravitreal bevacizumab injections administered as needed (PRN group) and initial treatment with 3 monthly injections followed by as-needed injections (3 monthly initial dose group) in patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO).Methods. This retrospective study included 69 and 26 patients in the PRN and 3 monthly initial dose groups, respectively. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were compared between the 2 groups 6 months after initial injection.Results. At month 6, BCVA change from baseline was-0.27±0.28(mean ± standard deviation) logMAR in the PRN group and-0.28±0.20 logMAR in the 3 monthly initial dose group. Mean CRT changes were-204±168in the PRN group and-161±149 μm in the 3 monthly initial dose group at month 6. There were no statistically significant differences in BCVA or CRT changes between groups at any time point. The number of intravitreal injections over 6 months was significantly lower in the PRN group (1.8±0.8injections) than in the 3 monthly initial dose group (3.4±0.5injections;P<0.001).Conclusions. Our results suggest that as-needed intravitreal bevacizumab injections are more tolerable for patients with ME secondary to BRVO.

Download Full-text

Management of macular edema due to branch retinal vein occlusion with intravitreal injections of pegaptanib sodium

Acta Ophthalmologica ◽

10.1111/j.1755-3768.2009.2411.x ◽

2009 ◽

Vol 87 ◽

pp. 0-0

Author(s):

R GALLEGO-PINAZO ◽

M DIAZ-LLOPIS ◽

E FRANCES-MUNOZ ◽

P UDAONDO-MIRETE ◽

D SALOM ◽

...

Keyword(s):

Macular Edema ◽

Retinal Vein Occlusion ◽

Branch Retinal Vein Occlusion ◽

Intravitreal Injections ◽

Pegaptanib Sodium ◽

Vein Occlusion

Download Full-text

Long-term Efficacy of Vitrectomy for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients Treated with Intravitreal Injections

Journal of the Korean Ophthalmological Society ◽

10.3341/jkos.2017.58.5.546 ◽

2017 ◽

Vol 58 (5) ◽

pp. 546

Author(s):

In Hwan Cho ◽

Un Chul Park ◽

Hyeong Gon Yu

Keyword(s):

Macular Edema ◽

Retinal Vein Occlusion ◽

Branch Retinal Vein Occlusion ◽

Intravitreal Injections ◽

Term Efficacy ◽

Vein Occlusion

Download Full-text

Correlation between macular vessel density and number of intravitreal anti-VEGF agents for macular edema associated with branch retinal vein occlusion

Scientific Reports ◽

10.1038/s41598-019-52732-2 ◽

2019 ◽

Vol 9 (1) ◽

Cited By ~ 1

Author(s):

Ryo Tomita ◽

Takeshi Iwase ◽

Kensuke Goto ◽

Kentaro Yamamoto ◽

Eimei Ra ◽

...

Keyword(s):

Regression Analysis ◽

Macular Edema ◽

Retinal Vein Occlusion ◽

Branch Retinal Vein Occlusion ◽

Vessel Density ◽

Intravitreal Injections ◽

Systemic Hypertension ◽

Vein Occlusion ◽

Anti Vegf ◽

The Mean

Abstract We evaluated whether the reduction of macular vessel density was correlated with the number of intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents in eyes with a branch retinal vein occlusion (BRVO). The mean vessel density was determined by optical coherence tomography angiography in 29 eyes with macular edema associated with a BRVO. Our results showed that the mean vessel density in the group that had a resolution of the macular edema after one anti-VEGF injection was significantly higher than group that had a recurrence of the macular edema (P = 0.028). Single regression analysis showed that the number of intravitreal injections was significantly correlated with the reduction of the modified vessel density (r = −0.421, P = 0.023) and systemic hypertension (r = 0.377, P = 0.044). Multiple stepwise regression analysis showed that the reduction of the modified vessel density (β = −0.442, P = 0.009) and hypertension (β = 0.403, P = 0.016) were independent factors associated with the number of intravitreal injections. We conclude that the vessel density reduction can be used to predict whether recurrences of the macular edema will develop after the initial anti-VEGF injection in eyes with macular edema associated with a BRVO.

Download Full-text

ANGIOGRAPHIC RISK FACTORS FOR RECURRENCE OF MACULAR EDEMA ASSOCIATED WITH BRANCH RETINAL VEIN OCCLUSION

Retina ◽

10.1097/iae.0000000000003026 ◽

2020 ◽

Vol Publish Ahead of Print ◽

Author(s):

Takahiro Kogo ◽

Yuki Muraoka ◽

Akihito Uji ◽

Sotaro Ooto ◽

Tomoaki Murakami ◽

...

Keyword(s):

Risk Factors ◽

Macular Edema ◽

Retinal Vein Occlusion ◽

Branch Retinal Vein Occlusion ◽

Vein Occlusion ◽

Risk Factors For Recurrence

Download Full-text

Association between capillary congestion and macular edema recurrence in chronic branch retinal vein occlusion through quantitative analysis of OCT angiography

Scientific Reports ◽

10.1038/s41598-021-99429-z ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Min Seung Kang ◽

Sang Yoon Kim ◽

Sung Who Park ◽

Ik Soo Byon ◽

Han Jo Kwon

Keyword(s):

Risk Factors ◽

Macular Edema ◽

Retinal Vein Occlusion ◽

Medical Records ◽

Branch Retinal Vein Occlusion ◽

Vein Occlusion ◽

Stable Period ◽

Risk Factors For Recurrence ◽

Tomographic Angiography ◽

Recurrence Group

AbstractThis study aims to quantitatively investigate the optical coherence tomographic angiography (OCTA) findings of capillary congestion and its association with macular edema (ME) recurrence in chronic branch retinal vein occlusion (BRVO). We retrospectively reviewed the medical records of 115 consecutive patients with major ischemic BRVO who reached stable macula (without ME for two consecutive visits) at baseline (the first visit within the stable period). All patients were classified into a recurrence or non-recurrence groups depending on ME recurrence. Capillary congestion of deep capillary plexuses (DCP-C) and other abnormal capillary lesions were segmented, and their areas, vascular densities, and mean retinal thicknesses (MRT) were calculated. The main outcomes were differences between the two groups and risk factors for recurrence among baseline and OCTA parameters. A total of 76 eyes were included, of which 22 (28.9%) recurred. DCP-C existed in all eyes at baseline. MRT of DCP-C (p = 0.006) was greater in the recurrence group. Greater MRT of DCP-C (OR: 1.044; p = 0.002) and more frequent intravitreal injections (OR: 1.803; p < 0.001) were associated with a higher risk of relapsing ME. DCP-C may contribute to the anatomical stability of chronic BRVO and simultaneously be the source of ME.

Download Full-text

Risk factors for repeated dexamethasone intravitreal implant therapy for macular edema due to treatment-naïve branch retinal vein occlusion

BMC Ophthalmology ◽

10.1186/s12886-021-01904-8 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Yu-Te Huang ◽

Chun-Ju Lin ◽

Huan-Sheng Chen ◽

Peng-Tai Tien ◽

Chun-Ting Lai ◽

...

Keyword(s):

Risk Factors ◽

Macular Edema ◽

Retinal Vein Occlusion ◽

Branch Retinal Vein Occlusion ◽

Older Age ◽

Repeated Treatment ◽

Dexamethasone Intravitreal Implant ◽

Vein Occlusion ◽

Intravitreal Implant ◽

Treatment Naïve

Abstract Background This study evaluated the effects of dexamethasone intravitreal implant on treatment-naïve branch retinal vein occlusion (BRVO)-induced macular edema (ME), and the risk factors for earlier repeated treatment. Methods Patients treated from 2013 to 2016 were enrolled. The patients’ demographics, medical history, best-corrected visual acuity (BCVA), and central retinal thickness (CRT) were recorded. Risk factors for repeated treatment were identified using a Cox proportional hazard model and logistic regression. Results 29 patients (mean age: 58.64 ± 13.3 years) were included; 44.8% received only one injection, while 55.2% received two or more. The mean initial CRT was 457.8 ± 167.1 μm; the peak CRT and final CRT improved significantly to 248.9 ± 57.9 μm and 329.2 ± 115.1 μm, respectively. The peak BCVA improvement and final improvement were 29.5 ± 23.5 approximate ETDRS letters and 19.8 ± 24.4 letters, respectively, with 62.1% of patients improving by more than 15 letters. Older age, higher initial CRT, and diabetes were the risk factors for multiple injections. Conclusion Dexamethasone intravitreal implant results in significant peak CRT and BCVA improvements, while older age, higher initial CRT, and diabetes are risk factors for repeated injections. The optimal retreatment schedule for these patients should be further explored.

Download Full-text